Navigation Links
Neuralstem Receives Notice of Patent Allowance for Spinal Cord Delivery Platform
Date:10/12/2011

h its cell therapy platform, including spinal cord injury, ischemic spastic paraplegia, chronic stroke, and Huntington's disease. The company has submitted an IND (Investigational New Drug) application to the FDA for a Phase I safety trial in chronic spinal cord injury.

Neuralstem also has the ability to generate stable human neural stem cell lines suitable for the systematic screening of large chemical libraries. Through this proprietary screening technology, Neuralstem has discovered and patented compounds that may stimulate the brain's capacity to generate new neurons, possibly reversing the pathologies of some central nervous system conditions.  Neuralstem's first small molecule compound, NSI-189 is currently in a Phase I FDA-approved safety trial in major depressive disorder.  The Phase Ib portion of the trial, in depressed patients, is expected to commence later this year. Additional indications could include schizophrenia, Alzheimer's disease and bipolar disorder.

For up-to-date information on the clinical trial for ALS and other Neuralstem cell therapy and pharmaceutical treatments in development, visit www.neuralstem.com

Cautionary Statement Regarding Forward Looking Information

This news release may contain forward-looking statements made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements in this press release regarding potential applications of Neuralstem's technologies constitute forward-looking statements that involve risks and uncertainties, including, without limitation, risks inherent in the development and commercialization of potential products, uncertainty of clinical trial results or regulatory approvals or clearances, need for future capital, dependence upon collaborators and maintenance of our intellectual property rights. Actual results may differ ma
'/>"/>

SOURCE Neuralstem, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Neuralstem President and CEO to Present at the 2011 Stifel Nicolaus Annual Healthcare Conference
2. Neuralstem Awarded Department of Defense Contract for Brain Cancer Research
3. Neuralstem Reports First Quarter Financial Results and Provides Business and Clinical Update
4. Former Capital One Director and Business Leader Stanley I. Westreich Joins Neuralstems Board
5. Neuralstem, Inc. Settles Litigation Against ReNeuron, Ltd.
6. Neuralstem, Inc. to Present At World Stem Cells and Regenerative Medicine Congress
7. Neuralstem Completes $5.25 Million Financing
8. Neuralstem, Inc. Reports Third Quarter Financial Results and Provides Business Update
9. Neuralstem Receives FDA Approval to Commence First ALS Stem Cell Trial
10. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Neuralstem, Inc.
11. Neuralstem to Present at the 11th Annual BIO CEO & Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2014)... Available spectra is similar for ... and cultivation of a wide range of plants. ... with proven patented and pending wide spectrum technology. ... in critical applications in contrast to growth spectra ... customers have a large variety of differently sized ...
(Date:8/29/2014)... Electronic circuits are based on electrons, but one of ... photonic circuits, i.e. circuits based on light (photons) instead ... to create a stream of single photons and control ... sorts of attempts to achieve this control, but now ... creating a steady stream of photons emitted one at ...
(Date:8/29/2014)... 29, 2014 Local veterinarian, Dr. Keith ... are seeking candidates to participate in an investigational study ... The ultimate goal of this study is to determine ... one or two arthritically affected joints can help reduce ... Candidates for the current investigational study must be older ...
(Date:8/28/2014)... (PRWEB) August 28, 2014 SPIE Fellow ... Physics and Optical Science and Director of the Center ... North Carolina at Charlotte, and co-founder and Chairman of ... serve as the 2015 Vice President of SPIE, the ... President Philip Stahl announced recent election results at the ...
Breaking Biology Technology:Breakthrough in light sources for new quantum technology 2Burnt Hills Veterinary Hospital Seeks Candidates for an Investigational Study of Stem Cells for Dogs with Arthritis 2Glenn Boreman, UNC Professor and Plasmonics Co-Founder, Elected to SPIE Presidential Chain 2
... SAN FRANCISCO, May 22 Takeda San ... Haak-Frendscho, Ph.D., as president,and chief scientific officer. ... activities at Takeda San Francisco including overall ... operations for,antibody therapeutics., Takeda San Francisco ...
... ... Emerging Pattern, NORTH BERGEN, N.J., ... Friday, 20 people arrived, one by one, for emergency care at,the ... nausea and diarrhea., A coincidence? Or the harbinger of a ...
... AstraZeneca (NYSE:,AZN) announced today that it supports ... the company,s latest step to provide the public,with ... Sponsored by Sens. Charles Grassley of Iowa ... a national registry of payments that,biopharmaceutical companies, device ...
Cached Biology Technology:Takeda's Antibody Therapeutics Research Company, Takeda San Francisco, Inc. Appoints Mary Haak-Frendscho, Ph.D. as President and CSO 2E. coli Outbreak in New Jersey? 2E. coli Outbreak in New Jersey? 3AstraZeneca Supports Transparency Legislation on Payments to Health Care Providers 2
(Date:8/29/2014)... Texas Medical Branch at Galveston has gone on record stating ... monkeys against a lethal dose of Ebola virus up to ... is severe. , Thomas Geisbert, professor of microbiology and immunology, ... in Ebola treatment research. The filoviruses known as Ebola virus ... with fatality rates of up to 90 percent. ...
(Date:8/29/2014)... German . ... the oldest form of communication. Acting as messenger molecules, ... sexual attraction between males and females. Fish rely on ... behavior in males and females. Scientists at the Marine ... Faro, Portugal, and at the Max Planck Institute for ...
(Date:8/29/2014)... USA - The rise of the Tibetan plateau -- ... -- is important for both its profound effect on ... study published in GSA Bulletin , Katharine Huntington ... isotope thermometry -- using modern and fossil snail shells ... in southwestern Tibet. , Views range widely on ...
Breaking Biology News(10 mins):Leading Ebola researcher at UTMB says there's an effective treatment for Ebola 2Ready for mating at the right time 2Ready for mating at the right time 3Snails tell of the rise and fall of the Tibetan Plateau 2Snails tell of the rise and fall of the Tibetan Plateau 3Snails tell of the rise and fall of the Tibetan Plateau 4Snails tell of the rise and fall of the Tibetan Plateau 5Snails tell of the rise and fall of the Tibetan Plateau 6Snails tell of the rise and fall of the Tibetan Plateau 7
... Whip spiders, considered by many to be creepy-crawly, are ... In two species of whip spiders, or amblypygids, mothers ... until they reach sexual maturity, and all mix in ... long-thought to be purely aggressive and anti-social, according to ...
... at the Carnegie Institution's Department of Plant Biology ... govern nutrient regulation—neighboring pore-like structures at the cell's ... a vital nutrient, nitrogen. It is the first ... neighboring molecules is essential to this regulation. Since ...
... syndrome are often seen laughing and smiling, but this ... problems and seizures. , ,ew research in ... be alleviated. , Edwin Weeber, Ph.D., and colleagues ... Angelman syndrome by preventing the inhibition of CaMKII, an ...
Cached Biology News:A rarity among arachnids, whip spiders have a sociable family life 2A rarity among arachnids, whip spiders have a sociable family life 3New mechanism for nutrient uptake discovered 2New mechanism for nutrient uptake discovered 3Angelman syndrome deficits rescued in mice 2Angelman syndrome deficits rescued in mice 3
Form: Ready to use Applications: ELISA...
EnzChek Ultra Xylanase Assay Kit *500 assays*...
Goat polyclonal to p27 KIP 1 ( Abpromise for all tested applications). Antigen: Synthetic peptide: C-KRPATDDS STQNK, corresponding to Internal sequence amino acids 153-165 of Human p27 KIP 1 ...
Defender against cell death 1...
Biology Products: